Tb-500

Overview

TB-500 is a synthetic version of thymosin beta-4, a naturally occurring peptide tied to tissue repair and regeneration. It promotes faster healing, reduces inflammation, and is popular with athletes who want to recover more quickly. Like most peptides, it is a research chemical requiring reconstitution and subcutaneous injection, so purity and storage genuinely matter.

Quick Verdict

Racehorses came first, then biohackers. TB-500 has a deep bench of veterinary evidence for tissue repair and a growing pile of human self-experimentation reports, but essentially no human clinical trials for the uses the biohacking crowd cares about. It is often paired with BPC-157 in the popular 'healing stack,' where it tackles repair from a complementary angle: systemic rather than local.

Evidence Quality

Human trials are weak. Thymosin beta-4 itself has some clinical data for wound healing and dry eye, but TB-500 as used in biohacking does not travel the same regulatory path. Animal evidence is strong, especially the extensive equine research. Community reports are strong and consistent, particularly for soft-tissue injury recovery. The big open question is whether the angiogenesis and cell migration TB-500 promotes could also feed an existing but undetected tumor.

What the Research Shows

Studies indicate TB-500 meaningfully accelerates healing by boosting collagen production and cell migration. One study found that the metabolite Ac-LKKTE actually matters more for wound healing than TB-500 itself. Pharmacological research suggests it acts systemically rather than locally, so injection site matters less than it does with BPC-157. The veterinary data is extensive enough that no one doubts the biological activity. What is missing is controlled human data on dosing, timing, and safety for the specific injuries people self-treat. Much of the existing research actually focuses on detection methods for doping control.

Who Should Be Cautious

The same cancer and angiogenesis concern that hangs over BPC-157 applies here, possibly even more so. Anyone with a cancer history, an active malignancy, or a family history of vascular tumors should steer clear. People with cardiovascular disease should also weigh the angiogenesis angle.

Cited Studies

A UHPLC mass-spectrometry study quantifying TB-500 and its metabolites found the metabolite Ac-LKKTE plays a bigger role in wound healing than TB-500 itself. Metabolism research in humans and horses established detection methods for doping control. An LC-MS study built the first doping-control method to catch TB-500 misuse in horses. And a thymosin beta-4 wound-healing study showed TB-500 speeds repair by driving collagen production and cell migration.

Community Sentiment

Across 843 community reports, sentiment is 51% positive, 37% neutral, and 12% negative, with mention volume up 347% year over year. Top reported effects include recovery, reduced inflammation, accelerated healing, pain relief, and easing elbow pain. Reported side effects include severe anxiety, concern about supporting tumor growth, injection-site itching, diarrhea, increased sweating, and product degradation. Of 7 users who reported more than once over a median of 39 days, 1 grew more positive, 5 stayed about the same, and 1 grew more negative.

Dosage Notes

A loading phase of 4 to 10 mg per week for 4 to 6 weeks is common, followed by maintenance at 2 to 5 mg per week. It is injected subcutaneously or intramuscularly.

Availability

It is sold as a research chemical by peptide suppliers, is not FDA-approved, and is widely available across the peptide marketplace.

Bottom Line

The biological activity is real and the veterinary record is robust, but the human clinical evidence and the 'healing stack' protocols are unproven. The cancer-promotion question alone is reason for caution.